French Spirits Maker Remy Cointreau's Long-Term And Issue Ratings Raised To 'BB' From 'BB-'; Outlook Stable Jan 12

  • ID: 2041648
  • January 2012
  • Region: France
  • Standard & Poors
1 of 3

French spirits manufacturer R-my Cointreau S.A.'s strong operating performance has markedly improved its credit metrics. We believe the group will continue to post solid results driven by the continuous positive momentum of its cognac division over the next 12 months, especially in China. We are raising our long-term corporate credit and issue ratings on R-my Cointreau to 'BB' from 'BB-'. The stable outlook reflects our expectation that R-my Cointreau will continue to perform solidly over the next 12 months. We believe this should enable the group to keep adjusted leverage below 3x and adequate headroom under its leverage covenant, despite what we view as an aggressive financial policy. MADRID (Standard & Poor's) Jan. 19, 2012--Standard & Poor's Ratings Services said...

Companies mentioned in this report are: Remy Cointreau S.A.
Action: Upgraded

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research type: News
This product is a is a brief one-page announcement of no more than 500 words with a quote from the analyst. It is media and investor focused with no accompanying commentary article.

Note: Product cover images may vary from those shown
2 of 3

Remy Cointreau S.A.

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown




Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.